18/06/2026 GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis (Ref) GRI Bio announced that the US FDA had granted Orphan Drug Designation to Tazarotene (GRI-062; oral RARβ/γ-selective agonist) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The designation marked a significant regulatory milestone and provided a potential pathway to se

26/02/2026 GSK’s linerixibat accepted for Priority review by China’s NMPA in patients with PBC Boehringer acquired an exclusive license for a novel oral therapeutics program for immune diseases from Sitryx Argenx announced topline results from Phase 3 trial of VYVGART in Ocular myasthenia gravis Soligenix received a positive opinion from the EMA on its request for orphan drug designation for SGX945 for the treatment of behçet's disease GSK’s linerixibat accepted for Priority